{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:36:12Z","timestamp":1787016972260,"version":"build-2736575974"},"reference-count":38,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T00:00:00Z","timestamp":1750550400000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["7254398"],"award-info":[{"award-number":["7254398"]}]},{"name":"National Scientific Data Sharing Platform for Population and Health","award":["NCMI-YF01N-201906"],"award-info":[{"award-number":["NCMI-YF01N-201906"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,6,11]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pancreatic adenosquamous cancer (PASC) is an extremely rare subtype of pancreatic cancer characterized by a poorer prognosis and higher likelihood of metastasis compared with the more prevalent pancreatic ductal adenocarcinoma (PDAC). Although genomic changes during PASC tumorigenesis have been documented, the corresponding alterations in the tumor immune microenvironment (TIME) remain inadequately elucidated. Therefore, this study aims to analyze the immune landscape of PASC by employing multiplex immunohistochemistry (mIHC) and digital image analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we analyzed four independent cohorts comprising 120 patients with PASC and 386 patients with PDAC. We employed mIHC to quantify three in situ panels of immuno-oncology-related biomarkers at subcellular resolution. We then used five samples to perform laser capture microdissection, RNA sequencing, and whole-exome sequencing to explore the underlying mechanisms of the compartment-specific immune phenotypes in PASC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our findings revealed a more immunosuppressive TIME in PASC compared with PDAC, characterized by a decreased abundance of T cells. Immune cell types indicative of enhanced immune surveillance, including cytotoxic and memory T cells and antigen-experienced T cells, were present at significantly lower densities in PASC compared with PDAC. Conversely, some immunosuppressive macrophage phenotypes exhibited increased distribution in PASC. Immunosuppressive immune cells (ICs) were abundant, enriched within stromal regions, highly heterogeneous across tumors, and exhibited distinct distributions between squamous cell (SQC) and adenocarcinoma (ADC) compartments in PASC. Notably, the TIME of SQC compartments harbored more exhausted T cells compared with synchronous ADC compartments, indicating attenuated immune surveillance during squamous transformation. Transcriptomic profiling of microdissected SQC and ADC regions revealed immune exhaustion signatures and downregulated T-cell differentiation pathways in SQC compartments, alongside altered antigen presentation machinery and elevated tumor mutational burden, suggesting squamous-specific tumor-associated antigens with potential immunotherapeutic relevance. Beyond differences in IC density, we observed closer spatial proximity of CD45RO\n                      <jats:sup>+<\/jats:sup>\n                      and PD-1\n                      <jats:sup>+<\/jats:sup>\n                      CD3\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells to tumor cells within 10, 20 and 30\u2009\u00b5m ranges in PASC compared with PDAC, with variations by histological subregion. Furthermore, we found distinct expression patterns of the programmed cell death protein-1 (PD-1)\/programmed death ligand 1 (PD-L1) and T-cell immunoreceptor with immunoglobulin and the ITIM domain (TIGIT)\/CD155 axes in the PASC TIME associated with survival outcomes. Notably, TIGIT\n                      <jats:sup>+<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells and CD155\n                      <jats:sup>+<\/jats:sup>\n                      CD68\n                      <jats:sup>+<\/jats:sup>\n                      macrophages, along with their proximity to tumor cells, served as independent prognostic indicators. These findings were validated in an independent cohort study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study advances the understanding of PASC by providing updated insights into its immunoenvironmental features. These findings underscore the potential of targeting immune checkpoint pathways, particularly the TIGIT\/CD155 and PD-1\/PD-L1 axes, as a therapeutic strategy for PASC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-012066","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T14:15:24Z","timestamp":1750688124000},"page":"e012066","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Attenuated immune surveillance during squamous cell transformation of pancreatic adenosquamous cancer defines new therapeutic opportunity for cancer interception"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct03563716","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9191-2521","authenticated-orcid":false,"given":"Xinyuan","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Pathology, Peking Union Medical College Hospital, Beijing, Beijing, China"},{"name":"Key Laboratory of Research in Pancreatic Tumor, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanyue","family":"Sun","sequence":"additional","affiliation":[{"name":"Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2747-9501","authenticated-orcid":false,"given":"Shuofeng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Liver Surgery, Peking Union Medical College Hospital, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangni","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Peking Union Medical College Hospital, Beijing, Beijing, China"},{"name":"Key Laboratory of Research in Pancreatic Tumor, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2658-9525","authenticated-orcid":false,"given":"Jie","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Peking Union Medical College Hospital, Beijing, Beijing, China"},{"name":"Key Laboratory of Research in Pancreatic Tumor, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianlong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Peking Union Medical College Hospital, Beijing, Beijing, China"},{"name":"Key Laboratory of Research in Pancreatic Tumor, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,23]]},"reference":[{"key":"2026052722354127000_13.6.e012066.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"2026052722354127000_13.6.e012066.2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jso.25112","article-title":"Comparative outcomes of adenosquamous carcinoma of the pancreas: An analysis of the National Cancer Database","volume":"118","author":"Hester","year":"2018","journal-title":"J Surg Oncol"},{"key":"2026052722354127000_13.6.e012066.3","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jss.2011.06.015","article-title":"415 patients with adenosquamous carcinoma of the pancreas: a population-based analysis of prognosis and survival","volume":"174","author":"Boyd","year":"2012","journal-title":"J Surg Res"},{"key":"2026052722354127000_13.6.e012066.4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00423-010-0677-3","article-title":"Clinicopathological features of adenosquamous pancreatic cancer","volume":"396","author":"Regi","year":"2011","journal-title":"Langenbecks Arch Surg"},{"key":"2026052722354127000_13.6.e012066.5","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/MPA.0000000000000089","article-title":"Clinical characteristics of adenosquamous carcinoma of the pancreas: a matched case-control study","volume":"43","author":"Imaoka","year":"2014","journal-title":"Pancreas"},{"key":"2026052722354127000_13.6.e012066.6","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3548"},{"key":"2026052722354127000_13.6.e012066.7","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2009.15"},{"key":"2026052722354127000_13.6.e012066.8","doi-asserted-by":"publisher","DOI":"10.1002\/path.4943"},{"key":"2026052722354127000_13.6.e012066.9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01878","article-title":"Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options","volume":"9","author":"Kabacaoglu","year":"2018","journal-title":"Front Immunol"},{"key":"2026052722354127000_13.6.e012066.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.08.004"},{"key":"2026052722354127000_13.6.e012066.11","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0363-5"},{"key":"2026052722354127000_13.6.e012066.12","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.58886"},{"key":"2026052722354127000_13.6.e012066.13","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1674"},{"key":"2026052722354127000_13.6.e012066.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0258"},{"key":"2026052722354127000_13.6.e012066.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.07.007"},{"key":"2026052722354127000_13.6.e012066.16","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.572420"},{"key":"2026052722354127000_13.6.e012066.17","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.7150\/thno.86547","article-title":"The spatial coexistence of TIGIT\/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma","volume":"13","author":"Ma","year":"2023","journal-title":"Theranostics"},{"key":"2026052722354127000_13.6.e012066.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00226-1"},{"key":"2026052722354127000_13.6.e012066.19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2607"},{"key":"2026052722354127000_13.6.e012066.20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1588"},{"key":"2026052722354127000_13.6.e012066.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.01.031"},{"key":"2026052722354127000_13.6.e012066.22","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-025-07388-4","article-title":"TIGIT expression in extrahepatic cholangiocarcinoma and its impact on CD8\u2009+\u2009T cell exhaustion: implications for immunotherapy","volume":"16","author":"Tang","year":"2025","journal-title":"Cell Death Dis"},{"key":"2026052722354127000_13.6.e012066.23","doi-asserted-by":"crossref","first-page":"108884","DOI":"10.1016\/j.biopha.2019.108884","article-title":"CD155 expression and its prognostic value in postoperative patients with breast cancer","volume":"115","author":"Yong","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"2026052722354127000_13.6.e012066.24","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-010-1378-5"},{"key":"2026052722354127000_13.6.e012066.25","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4251\/wjgo.v7.i9.132","article-title":"Adenosquamous carcinoma of the pancreas: Molecular characterization of 23 patients along with a literature review","volume":"7","author":"Borazanci","year":"2015","journal-title":"World J Gastrointest Oncol"},{"key":"2026052722354127000_13.6.e012066.26","doi-asserted-by":"crossref","first-page":"741","DOI":"10.18632\/oncotarget.28659","article-title":"A case of adenosquamous pancreatic cancer with a KRAS G12C mutation with an exceptional response to immunotherapy","volume":"15","author":"Ahmed","year":"2024","journal-title":"Oncotarget"},{"key":"2026052722354127000_13.6.e012066.27","doi-asserted-by":"crossref","first-page":"1456343","DOI":"10.3389\/fimmu.2024.1456343","article-title":"Case report: Microsatellite instability-high pancreas adenosquamous carcinoma with postoperative liver metastasis recurrence treated with multimodality therapy achieving complete pathological response","volume":"15","author":"Liu","year":"2024","journal-title":"Front Immunol"},{"key":"2026052722354127000_13.6.e012066.28","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1721810","article-title":"PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models","volume":"9","author":"Yamazaki","year":"2020","journal-title":"Oncoimmunology"},{"key":"2026052722354127000_13.6.e012066.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09415-3"},{"key":"2026052722354127000_13.6.e012066.30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan3682","article-title":"In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy","volume":"10","author":"Wang","year":"2018","journal-title":"Sci Transl Med"},{"key":"2026052722354127000_13.6.e012066.31","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S1470-2045(24)00679-X","article-title":"Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study","volume":"26","author":"Finn","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026052722354127000_13.6.e012066.32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32540-1"},{"key":"2026052722354127000_13.6.e012066.33","doi-asserted-by":"crossref","DOI":"10.1038\/s41523-025-00728-9","article-title":"Spatial proximity of CD8+ T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer","volume":"11","author":"Liang","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"2026052722354127000_13.6.e012066.34","doi-asserted-by":"publisher","DOI":"10.3892\/ijo_figS0788"},{"key":"2026052722354127000_13.6.e012066.35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004219","article-title":"Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer","volume":"10","author":"Zhu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026052722354127000_13.6.e012066.36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.588552","article-title":"PD-L1-Mediated Immunosuppression in Glioblastoma Is Associated With the Infiltration and M2-Polarization of Tumor-Associated Macrophages","volume":"11","author":"Zhu","year":"2020","journal-title":"Front Immunol"},{"key":"2026052722354127000_13.6.e012066.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2022.07.004"},{"key":"2026052722354127000_13.6.e012066.38","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1016\/j.ymthe.2021.03.013","article-title":"Inhibition of xCT suppresses the efficacy of anti-PD-1\/L1 melanoma treatment through exosomal PD-L1-induced macrophage M2 polarization","volume":"29","author":"Liu","year":"2021","journal-title":"Mol Ther"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:35:53Z","timestamp":1779946553000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,23]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/jitc-2025-012066"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012066","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}